首页> 美国卫生研究院文献>Human Molecular Genetics >14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening
【2h】

14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening

机译:14-3-3蛋白调节突变的LRRK2激酶活性和神经突缩短

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of inherited Parkinson's disease (PD), and LRRK2 is a risk factor for idiopathic PD. How LRRK2 function is regulated is not well understood. Recently, the highly conserved 14-3-3 proteins, which play a key role in many cellular functions including cell death, have been shown to interact with LRRK2. In this study, we investigated whether 14-3-3s can regulate mutant LRRK2-induced neurite shortening and kinase activity. In the presence of 14-3-3θ overexpression, neurite length of primary neurons from BAC transgenic G2019S-LRRK2 mice returned back to wild-type levels. Similarly, 14-3-3θ overexpression reversed neurite shortening in neuronal cultures from BAC transgenic R1441G-LRRK2 mice. Conversely, inhibition of 14-3-3s by the pan-14-3-3 inhibitor difopein or dominant-negative 14-3-3θ further reduced neurite length in G2019S-LRRK2 cultures. Since G2019S-LRRK2 toxicity is likely mediated through increased kinase activity, we examined 14-3-3θ's effects on LRRK2 kinase activity. 14-3-3θ overexpression reduced the kinase activity of G2019S-LRRK2, while difopein promoted the kinase activity of G2019S-LRRK2. The ability of 14-3-3θ to reduce LRRK2 kinase activity required direct binding of 14-3-3θ with LRRK2. The potentiation of neurite shortening by difopein in G2019S-LRRK2 neurons was reversed by LRRK2 kinase inhibitors. Taken together, we conclude that 14-3-3θ can regulate LRRK2 and reduce the toxicity of mutant LRRK2 through a reduction of kinase activity.
机译:富含亮氨酸的重复激酶2(LRRK2)中的突变是遗传性帕金森氏病(PD)的最常见已知原因,而LRRK2是特发性PD的危险因素。 LRRK2功能如何调节尚不完全清楚。最近,已显示高度保守的14-3-3蛋白在许多细胞功能(包括细胞死亡)中起关键作用,已与LRRK2相互作用。在这项研究中,我们调查了14-3-3s是否可以调节突变的LRRK2诱导的神经突缩短和激酶活性。在存在14-3-3θ过表达的情况下,来自BAC转基因G2019S-LRRK2小鼠的原代神经元的神经突长度返回到野生型水平。同样,BAC转基因R1441G-LRRK2小鼠的神经元培养物中14-3-3θ过表达逆转了神经突缩短。相反,在G2019S-LRRK2培养物中,pan-14-3-3抑制剂双磷蝶呤或显性负性14-3-3θ抑制14-3-3进一步减少了神经突长度。由于G2019S-LRRK2毒性可能是通过增加激酶活性介导的,因此我们检查了14-3-3θ对LRRK2激酶活性的影响。 14-3-3θ过表达降低了G2019S-LRRK2的激酶活性,而双磷灰质则促进了G2019S-LRRK2的激酶活性。 14-3-3θ降低LRRK2激酶活性的能力要求14-3-3θ与LRRK2直接结合。利福平在G2019S-LRRK2神经元中缩短神经突的作用被LRRK2激酶抑制剂逆转。两者合计,我们得出结论,14-3-3θ可以调节LRRK2,并通过降低激酶活性来降低突变体LRRK2的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号